* Bioatla Inc BCAB.OQ reported a quarterly adjusted loss
of 44
cents per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of -75
cents. The mean expectation of five analysts for the quarter
was for a loss of 44 cents per share. Wall Street expected
results to range from -51 cents to -35 cents per share.
* Reported revenue was zero; analysts expected zero.
* Bioatla Inc's reported EPS for the quarter was a loss
of 44
cents.
* The company reported a quarterly loss of $21.07 million.
* Bioatla Inc shares had risen by 1.5% this quarter and
lost 43.5%
so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 12.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Bioatla Inc is
$10.00
This summary was machine generated from LSEG data August 9 at
02:21 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.44 -0.44 Met
Mar. 31 2024 -0.54 -0.48 Beat
Dec. 31 2023 -0.79 -0.56 Beat
Sep. 30 2023 -0.80 -0.70 Beat